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Abstract: Protein C (PC) and its cofactor protein S (PS) are potent physiological anticoagulant 
mechanisms. As thrombotic events are known to be a major complication of the surgical procedures, we studied 
the behavior of these anticoagulant mechanisms in surgical patients.  PC:Ag level was significantly decreased 
(63,3 ± 4,2, p< 0,001) in 29 critically - ill surgical  patients when compared to 32 healthy control subjects. When 
compared to 10 controls subjects,  PS:Ag was also significantly decreased (59,2 ± 4,96, p< 0,01)  in 12 surgical 
patients in critical condition. These changes could be explained by the switch of the hepatic protein synthesis 
during the acute phase reaction developing in critically ill surgical patients towards the increased production of 
acute phase proteins, while reducing the secretion of PC and PS, cholinesterase and albumin. These observations 
emphasize the risk for thrombosis in postoperative states and stress the importance of a thorough investigation of 
hemostasis in surgical patients.  
 
INTRODUCTION 
 
 Blood coagulation is regulated by several anticoagulant mechanisms. One of these is 
represented  by the protein C system (3). Protein C is a vitamin K dependent serin protease 
secreted by the liver in an inactive form, which is activated by  thrombin bound to 
thrombomodulin (an endothelial glycoprotein). Once activated, protein C inactivates by 
proteolytic clivage clotting factors Va and VIIIa, exerting an important anticoagulant effect. 
Its action requires the presence of a cofactor, protein S, which is also a vitamin K dependent 
liver secreted protein. Only 40% of protein S circulates free in the plasma and acts as a 
cofactor for protein C, whereas 60% of plasma protein S is bound to c4bBP, a protein which 
also transports the c4b fraction of the complement. 
The physiological importance of the protein C system as an anticoagulant mechanism 
is demonstrated by the thrombotic events that occur in patients with deficiencies of either 
protein C or protein S (2, 4,10). Activated  protein C and the cofactors of the protein C 
pathway also exert a more recently revealed cytoprotective (antiinflammatory and 
antiapoptotic) activity due to direct effects on cells (11).  
As surgical procedures are well known for their high thrombotic risk, the behavior of 
protein C and protein S were investigated in critically ill surgical patients developing an acute 
phase reaction. Serum cholinesterase activity was also investigated, as a marker of hepatic 
proteosynthesis. 
MATERIAL AND METHODS 
 
Patients.  
For the protein C study: 
Control subjects. 32 healthy subjects (13 men, 19 women), aged 20- 60 years 
Critically ill surgical patients. 29 patients (19 men, 10 women), aged 26-79 years. Blood was 
colected 5-6 days after major abdominal surgery for mesenteric infarction (5 patients, 2 of 
them obese), colonic neoplasma (7 patients), gastric carcinoma (2 patients), strangulating 
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intestinal obstruction (3 patients),  acute peritonitis (3 patients), acute pancreatitis (3 patients), 
severe thoracic and abdominal trauma (6 patients). Only 2 subjects had low platelet count (< 
100x109/l) and low fibrinogen levels(< 1,5 g/l). All the patients were in a critical clinical 
condition; 12 of these patients had a lethal outcome in the intensive care unit.  
For the protein S study: 
Control subjects. 10 healthy subjects (4 men., 6 women), aged 27-62 years. 
Critically ill surgical patients. 12 patients (10 men, 2 women), aged 42-85 years. Blood was 
colected 5-9 days after major abdominal surgery for colonic neoplasma (1 patient), gastric 
neoplasma (2 patients), mesenteric infarction (2 patients), hydatid cyst of the liver (1 patient), 
retroperitoneal tumor (1 patient), acute peritonitis (4 patients). In spite of the relative 
heterogeneity of the group due to the different  etiology, all these subjects were in a clinical 
critical condition and displayed an acute phase reaction. None of these patients displayed 
signs of a disseminated intravascular coagulopathy.  
Methods. Blood was harvested in fasting conditions. Plasma  plasma protein C antigen and 
protein S antigen were measured in platelet poor citrated plasma (PPP). The samples were 
kept frozen at – 200C and rapidly thawed at 370C 30 minutes prior to the assay. PC:Ag and 
PS:Ag were measured using ELISA commercial kits from Asserachrom Diagnostica Stago 
(France). The kits were provided with their own standards. Serum cholinesterase activity was 
measured on a Beckman analyser. Fibrinogen was measured colorimetrically. 
Statistics. Results were expressed as mean ± standard error of the mean (SEM). Significance 
of differences between groups of results was calculated using the Student’s t-test.  
 
RESULTS 
  
As compared to the control group, plasma PC:Ag and serum cholinesterase activity 
were decreased in the critically ill surgical patients (Table 1). The 12 surgical patients with 
lethal outcome had lower levels of PC:Ag (53,4±5,66%) than the 17 survivors (70,3 ±5,07%), 
but the difference was not statistically significant.  
 
Table 1. 
 Serum cholinesterase (CHE) activity, plasma PC:Ag and plasma fibrinogen level in healthy control 
subjects and in critically ill surgical patients. Mean ± SEM. Significance versus control subjects *p<0,001 
 
Group Number of 
subjects 
Che 
activity(U/l) 
Fibrinogen 
(g/l) 
PC activity (% of standard 
plasma) 
Controls 32 8032 ± 501 2,57 ± 0,09 90,6 ± 2,8 
Critically 
ill 
29 3921 ± 411* 4,29 ± 0,42* 63,3 ± 4,21* 
 
Plasma PS:Ag was found to be significantly decreased in surgical patients when compared to 
control subjects (Table 2). Serum cholinesterase activity was also obviously diminished in surgical 
patients.  
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Table 2. 
 Serum cholinesterase (CHE) activity, plasma PS:Ag and plasma fibrinogen level in healthy control 
subjects and in critically ill surgical patients. Mean ± SEM. Significance versus control subjects  *p<0,001 
 
Group Number of 
subjects 
Che activity 
(U/l) 
Fibrinogen 
(g/l) 
PS activity (% of standard 
plasma) 
Controls 10 7966 ± 479 2,64 ± 0,14 80,4 ± 5,16 
Critically 
ill 
12 3650 ± 535* 5,42 ± 0,5* 59,23 ± 4,96* 
 
DISCUSSION 
 
 Decreased  levels of plasma protein C and plasma protein S were reported in critically 
ill surgical patients (5,7), but these findings were interpretated as a consequence of a 
persistent consumption. No attempt was made to associate this reduction with impaired or 
disregulated hepatic synthesis.  
In the present studies, the low levels of PC:Ag and PS:Ag, as well as reduced 
cholinesterase activity in patients without evidence of consumption coagulopathy are more 
suggestive for an impaired hepatic synthesis, in agreement with Rodeghiero (15). On the other 
hand, it is also possible that the acute phase reaction developed during the surgical procedure 
may cause a switch in the hepatic protein synthesis towards  the increased production of acute 
phase proteins (such as fibrinogen), while reducing the secretion of albumin, cholinesterase 
and presumably of protein C and protein S. Inflammatory mediators such as TNFa can  inhibit 
the protein C anticoagulant pathway, by down-regulating the expression of the protein C 
activation complex (thrombomodulin and the endothelial cell protein C receptor), and up-
regulating a1-antitrypsin (an inhibitor of activated protein C) (6). 
The clinical relevance of these observations should be interpretated in the context of 
an overall view, considering the other changes in the hemostasis parameters that occur during 
surgical procedures, such as antithrombin low levels, high levels of fibrinogen, factor VIII:c, 
von Willebrand factor (1, 13) and of fibrinolysis inhibitor PAI 1, which all contribute to a 
prothrombotic status.  
A new perspective for the clinical significance of the reduction of protein C and 
protein S levels is suggested by the recent studies concerning the role of the protein C 
pathway in inflammation and apoptosis. More recent basic and preclinical research on 
activated PC has characterized the direct cytoprotective effects of APC that involve gene 
expression profile alterations, anti-inflammatory and anti-apoptotic activities and endothelial 
barrier stabilization. These actions generally require endothelial cell protein C receptor 
(EPCR) and protease activated receptor-1. Because of these direct cytoprotective actions, 
activated PC reduces mortality in murine endotoxemia and severe sepsis models and provides 
neuroprotective benefits in murine ischemic stroke models. Furthermore, activated PC 
reduces mortality in patients with severe sepsis (PROWESS clinical trial)(9,12). According to 
Gierer (8), activated protein C reduces tisular inflammation, hypoxia and apoptosis in 
experimentaly injured  skeletal muscles. 
Until recently, the physiologic role of the PS-C4BP complex had remained uncertain. 
Some years ago, it was suggested that PS could act as a bridge between coagulation and 
inflammation, by localizing C4BP to negatively charged phospholipids and controlling 
complement proliferation at sites where the coagulation system was activated (14). 
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Considering these recent findings one may presume that in surgical patients the low 
levels of protein C and protein S subsequent to the acute phase reaction may  contribute not 
only to prothrombotic status, but also to the amplification of the inflammatory process. 
Because of these pleiotropic properties, activated PC and the protein C pathway 
components have important roles in both  regulation of the coagulation process and 
inflammatory response, and provide opportunities for therapeutic treatment of complex and 
challenging medical disorders, including thrombosis, severe sepsis and stroke. 
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